Multivalent, Saccharide‐Functionalized Gold Nanoparticles as Fully Synthetic Analogs of Type A Neisseria meningitidis Antigens
Source abstract
Abstract
Antigen analogs of polyclonal antibodies specific for type A Neisseria mengitidis are prepared by covering gold clusters (2–5 nm in size) with a monolayer of saccharides that have the structure of the repeating unit of the capsular polysaccharide of this bacterium. These systems may find use as synthetic antigens for immunostimulation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bacterial Infections and Vaccines · Nanocluster Synthesis and Applications · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. 10.1016/j.vaccine.2007.11.04210.1016/j.vaccine.2007.11.042 ↗
2. 10.1093/bmb/ldh04110.1093/bmb/ldh041 ↗
3. Jennings H. J. · 1983 · 155
4. Pozsgay V. · 2000 · 153
5. Ravenscroft N. · Curr. Opin. Drug Discovery Dev. · 2000 · 3 · 222
6. 10.1046/j.1469-0691.2003.00530.x10.1046/j.1469-0691.2003.00530.x ↗
7. 10.2174/138527200337611110.2174/1385272003376111 ↗
8. 10.1002/anie.20050159310.1002/anie.200501593 ↗
9. 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-310.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3 ↗
10. 10.1021/cr000418f10.1021/cr000418f ↗
11. 10.1021/ja072931h10.1021/ja072931h ↗
12. 10.1021/ja074804r10.1021/ja074804r ↗
13. 10.1002/(SICI)1521-3773(20000303)39:5<836::AID-ANIE836>3.0.CO;2-I10.1002/(SICI)1521-3773(20000303)39:5<836::AID-ANIE836>3.0.CO;2-I ↗
14. 10.1126/science.109520910.1126/science.1095209 ↗
15. 10.1002/cbic.20060007810.1002/cbic.200600078 ↗
16. 10.1021/ja027184x10.1021/ja027184x ↗
17. 10.1021/bc060107x10.1021/bc060107x ↗
18. 10.1073/pnas.060175510310.1073/pnas.0601755103 ↗
19. 10.1016/j.carres.2006.11.01810.1016/j.carres.2006.11.018 ↗
20. 10.1002/1521-3773(20010618)40:12<2257::AID-ANIE2257>3.0.CO;2-S10.1002/1521-3773(20010618)40:12<2257::AID-ANIE2257>3.0.CO;2-S ↗
21. 10.1016/j.bbagen.2005.12.00110.1016/j.bbagen.2005.12.001 ↗
22. 10.1016/j.tetasy.2004.12.00310.1016/j.tetasy.2004.12.003 ↗
23. 10.1021/ja010437m10.1021/ja010437m ↗
24. 10.1021/ja020090310.1021/ja0200903 ↗
25. 10.1021/la034358v10.1021/la034358v ↗
26. 10.1039/b507237a10.1039/b507237a ↗
27. 10.1039/B306366F10.1039/B306366F ↗
28. 10.1002/anie.20060258110.1002/anie.200602581 ↗
29. 10.1021/ja043547c10.1021/ja043547c ↗
30. 10.1002/anie.20046064910.1002/anie.200460649 ↗
31. 10.1021/la025982v10.1021/la025982v ↗
32. 10.1039/b005244m10.1039/b005244m ↗
33. 10.1039/b410476e10.1039/b410476e ↗
34. 10.1016/S1473-3099(04)01251-410.1016/S1473-3099(04)01251-4 ↗
35. 10.1002/chem.20060174310.1002/chem.200601743 ↗
36. 10.1021/la703558y10.1021/la703558y ↗
37. We have used the term “monolayer” rather than “monoshell” despite the fact that our thiols are probably not well packed as one might assume is the case with a monolayer. We prefer to maintain the term “monolayer” as it is common practice in this sort of nanoparticles.
38. We could not perform experiments with Type Y polysaccharide because the antibody used for the ELISA experiments is an anti‐mouse MenACWY and therefore can also recognize TypeY saccharides.
39. 10.1021/ja056053410.1021/ja0560534 ↗